Demographics
| Characteristic . | DA60 (n = 602) . | DA90 (n = 604) . |
|---|---|---|
| Age, y | ||
| 16-29 | 59 | 59 |
| 30-39 | 65 | 66 |
| 40-49 | 120 | 121 |
| 50-59 | 199 | 199 |
| 60+ | 159 | 159 |
| Median | 53 | 53 |
| Range | 16-72 | 16-72 |
| Sex | ||
| Female | 267 | 284 |
| Male | 335 | 320 |
| Diagnosis | ||
| De novo | 509 | 509 |
| Secondary | 59 | 59 |
| MDS | 34 | 36 |
| World Health Organization PS | ||
| 0 | 401 | 403 |
| 1 | 165 | 166 |
| 2 | 20 | 21 |
| 3 | 15 | 14 |
| 4 | 1 | 0 |
| White blood cell count | ||
| 0-9.9 | 320 | 312 |
| 10-49.9 | 175 | 175 |
| 50-99.9 | 65 | 65 |
| 100+ | 42 | 52 |
| Median | 8.0 | 9.3 |
| Range | 0.3-430.0 | 0.4-395.0 |
| Cytogenetics | ||
| Favorable | 60 | 52 |
| Intermediate | 410 | 417 |
| Adverse | 96 | 109 |
| Unknown | 36 | 26 |
| FLT3 ITD | ||
| WT | 458 | 462 |
| Mutant | 100 | 100 |
| Unknown | 44 | 42 |
| NPM1c | ||
| WT | 400 | 383 |
| Mutant | 153 | 167 |
| Unknown | 49 | 54 |
| ITD/NPM1c | ||
| ITD WT, NPM1c WT | 356 | 349 |
| ITD WT, NPM1c mutant | 97 | 102 |
| ITD mutant, NPM1c WT | 44 | 34 |
| ITD mutant, NPM1c mutant | 56 | 65 |
| Unknown | 49 | 54 |
| Post–course 1 risk score | ||
| Good risk | 80 | 63 |
| Standard risk | 255 | 257 |
| Poor risk | 219 | 214 |
| Not assessable* | 48 | 70 |
| Characteristic . | DA60 (n = 602) . | DA90 (n = 604) . |
|---|---|---|
| Age, y | ||
| 16-29 | 59 | 59 |
| 30-39 | 65 | 66 |
| 40-49 | 120 | 121 |
| 50-59 | 199 | 199 |
| 60+ | 159 | 159 |
| Median | 53 | 53 |
| Range | 16-72 | 16-72 |
| Sex | ||
| Female | 267 | 284 |
| Male | 335 | 320 |
| Diagnosis | ||
| De novo | 509 | 509 |
| Secondary | 59 | 59 |
| MDS | 34 | 36 |
| World Health Organization PS | ||
| 0 | 401 | 403 |
| 1 | 165 | 166 |
| 2 | 20 | 21 |
| 3 | 15 | 14 |
| 4 | 1 | 0 |
| White blood cell count | ||
| 0-9.9 | 320 | 312 |
| 10-49.9 | 175 | 175 |
| 50-99.9 | 65 | 65 |
| 100+ | 42 | 52 |
| Median | 8.0 | 9.3 |
| Range | 0.3-430.0 | 0.4-395.0 |
| Cytogenetics | ||
| Favorable | 60 | 52 |
| Intermediate | 410 | 417 |
| Adverse | 96 | 109 |
| Unknown | 36 | 26 |
| FLT3 ITD | ||
| WT | 458 | 462 |
| Mutant | 100 | 100 |
| Unknown | 44 | 42 |
| NPM1c | ||
| WT | 400 | 383 |
| Mutant | 153 | 167 |
| Unknown | 49 | 54 |
| ITD/NPM1c | ||
| ITD WT, NPM1c WT | 356 | 349 |
| ITD WT, NPM1c mutant | 97 | 102 |
| ITD mutant, NPM1c WT | 44 | 34 |
| ITD mutant, NPM1c mutant | 56 | 65 |
| Unknown | 49 | 54 |
| Post–course 1 risk score | ||
| Good risk | 80 | 63 |
| Standard risk | 255 | 257 |
| Poor risk | 219 | 214 |
| Not assessable* | 48 | 70 |
WT, wild-type.
Post–course 1 validated risk score22 is not available for patients who had induction death, had missing cytogenetics, or in whom a response to course 1 was not available.